Clover Biopharmaceuticals, Ltd. (HKG:2197)
Hong Kong · Delayed Price · Currency is HKD 1.910
-0.085 (-4.26%)
Sep 11, 2026, 4:08 PM HKT
Clover Biopharmaceuticals Revenue
Clover Biopharmaceuticals had revenue of 179.00K CNY in the half year ending June 30, 2026. This brings the company's revenue in the last twelve months to 430.00K, down -99.17% year-over-year. In the year 2025, Clover Biopharmaceuticals had annual revenue of 3.51M, down -90.88%.
Revenue (ttm)
430.00K CNY
Revenue Growth
-99.17%
P/S Ratio
4,995.68
Revenue / Employee
1.67K CNY
Employees
257
Market Cap
2.48B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.51M | -34.91M | -90.88% |
| Dec 31, 2024 | 38.42M | -836.00K | -2.13% |
| Dec 31, 2023 | 39.26M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Viva Biotech Holdings | 2.20B |
| Frontage Holdings | 2.18B |
| AIM Vaccine | 1.30B |
| Antengene Corporation | 652.54M |
| Medtide | 635.93M |
| BioDlink International Company | 582.45M |
| Laekna | 296.69M |
| HJ Science | 16.30M |
Clover Biopharmaceuticals News
- 5 months ago - Clover Biopharmaceuticals Reports Positive U.S. Phase I Data On RSV Re-Vaccination In Older Adults - Nasdaq